Citation:Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL 2012

Citation

Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012 Mar;21(3):456-61 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/22241250.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL 2012	Are there any treatments that prevent progression of BO to cancer?	Professor David Watson MBBS, MD, FRACS	completed
Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL 2012 2	What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?	Professor David Whiteman B Med Sci, MBBS (Hons) PhD FAFPHM	completed
Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL 2012 3	Are there groups of patients with non-dysplastic BO that require more frequent surveillance?	Dr Henry To	completed
Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL 2012 4	Are there groups of patients with BO that can be discharged from surveillance?	Conjoint Associate Professor Philip Craig	completed

Compare quality appraisals for each clinical question

• Are there any treatments that prevent progression of BO to cancer? (compare critical appraisals)
• What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma? (compare critical appraisals)
• Are there groups of patients with non-dysplastic BO that require more frequent surveillance? (compare critical appraisals)
• Are there groups of patients with BO that can be discharged from surveillance? (compare critical appraisals)

Cited by

1. What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?